Reading VRCA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VRCA free→Reading VRCA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VRCA free→QuarterlyIQ Insights · VRCA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The excerpt is incomplete and does not provide specific details about the event.
Results of Operations and Financial Condition. On May 12, 2026, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended March 31, 2026. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Results of Operations and Financial Condition. On March 11, 2026, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Charles Frantzreb as Director On December 26, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Charles Frantzreb to serve as a director of the Company effective immediately. Dr. Frantzreb will serve as a Class III director whose initial term is scheduled to expire at the 2027 an…
Entry Into A Material Definitive Agreement. Private Placement of Common Stock and Warrants On November 23, 2025, Verrica Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement with certain institutional investors (the “ Institutional Investor Purchase Agreement ”) and a Securities Purchase Agreement with other accredited investors (together with the Institutional Investor Purchase Agreement, the “ Purchase Agreements ” and the investors under the Purchase Agreeme…
Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreements as set forth under
Other Events. On November 24, 2025, the Company issued a press release announcing the Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On November 14, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this…
Results of Operations and Financial Condition. On August 12, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 24, 2025, The Nasdaq Stock Market LLC (“ Nasdaq ”) notified Verrica Pharmaceuticals Inc. (the “ Company ”) that, based upon the preceding 30-business day period, the Company no longer satisfied Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Global Marke…
Material Modification to Rights of Security Holders. (a) On July 22, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-10 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Annual Meeting of Stockholders held on June 5, 2025. Pursua…
Entry into a Material Definitive Agreement. On June 27, 2025 (the “Amendment Effective Date”), Verrica Pharmaceuticals Inc. (the “Company”) entered into the second amendment (the “Second Amendment”) to the Collaboration and License Agreement (the “Collaboration and License Agreement”) dated March 17, 2021 and previously amended on May 14, 2024, by and between the Company and Torii Pharmaceutical Co., Ltd. (“Torii” and together with the Company, the “Parties”). Pursuant to the Second Amendment…
Entry into a Material Definitive Agreement. On June 10, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) entered into the sixth amendment and waiver (the “ Sixth Amendment ”) to its Credit Agreement dated as of July 26, 2023 (as amended prior to the Sixth Amendment, the “ Credit Agreement ”), by and between the Company, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, as a lender, each other lender that may from time to time become a party thereto (collectively, the “ Lenders ”…
Results of Operations and Financial Condition. On May 13, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three months ended March 31, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Ex…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Christopher G. Hayes as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary On April 22, 2025, Christopher G. Hayes notified Verrica Pharmaceuticals Inc. (the “ Company ”) that he will resign from his positions as the Company’s Chief Legal Officer, Chief Compliance Officer and Corporate Secretary effective as of Apr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately. Dr. Corcoran will serve as a Class I director whose initial term is scheduled to expire at the 2025 annual meeting of stockholders. There is no arrangement…
Results of Operations and Financial Condition. On March 11, 2025, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securi…
Entry into a Material Definitive Agreement. On February 18, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) entered into a waiver (the “ Waiver ”) to its Credit Agreement dated as of July 26, 2023 (as amended prior to the Waiver, the “ Credit Agreement ”), by and between the Company, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrat…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.